The phosphatase Shp1 interacts with and dephosphorylates cortactin to inhibit invadopodia function.
Animals
Cell Line, Tumor
Cortactin
/ metabolism
Extracellular Matrix
/ metabolism
Humans
Inositol Phosphates
/ metabolism
Lung Neoplasms
/ secondary
Melanoma
/ metabolism
Mice, Inbred BALB C
Mice, Nude
Models, Biological
Neoplasm Invasiveness
Phosphorylation
Protein Binding
Protein Tyrosine Phosphatase, Non-Receptor Type 6
/ metabolism
Pseudopodia
/ metabolism
Substrate Specificity
Cancer
Cortactin
Glycerophosphoinositols
Invadopodia
Phosphoinositides
Src homology region 2 domain-containing phosphatase-1 (Shp1)
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
04 06 2021
04 06 2021
Historique:
received:
26
10
2020
accepted:
29
04
2021
entrez:
5
6
2021
pubmed:
6
6
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Invadopodia are actin-based cell-membrane protrusions associated with the extracellular matrix degradation accompanying cancer invasion. The elucidation of the molecular mechanisms leading to invadopodia formation and activity is central for the prevention of tumor spreading and growth. Protein tyrosine kinases such as Src are known to regulate invadopodia assembly, little is however known on the role of protein tyrosine phosphatases in this process. Among these enzymes, we have selected the tyrosine phosphatase Shp1 to investigate its potential role in invadopodia assembly, due to its involvement in cancer development. Co-immunoprecipitation and immunofluorescence studies were employed to identify novel substrate/s of Shp1AQ controlling invadopodia activity. The phosphorylation level of cortactin, the Shp1 substrate identified in this study, was assessed by immunoprecipitation, in vitro phosphatase and western blot assays. Short interference RNA and a catalytically-dead mutant of Shp1 expressed in A375MM melanoma cells were used to evaluate the role of the specific Shp1-mediated dephosphorylation of cortactin. The anti-invasive proprieties of glycerophosphoinositol, that directly binds and regulates Shp1, were investigated by extracellular matrix degradation assays and in vivo mouse model of metastasis. The data show that Shp1 was recruited to invadopodia and promoted the dephosphorylation of cortactin at tyrosine 421, leading to an attenuated capacity of melanoma cancer cells to degrade the extracellular matrix. Controls included the use of short interference RNA and catalytically-dead mutant that prevented the dephosphorylation of cortactin and hence the decrease the extracellular matrix degradation by melanoma cells. In addition, the phosphoinositide metabolite glycerophosphoinositol facilitated the localization of Shp1 at invadopodia hence promoting cortactin dephosphorylation. This impaired invadopodia function and tumor dissemination both in vitro and in an in vivo model of melanomas. The main finding here reported is that cortactin is a specific substrate of the tyrosine phosphatase Shp1 and that its phosphorylation/dephosphorylation affects invadopodia formation and, as a consequence, the ability of melanoma cells to invade the extracellular matrix. Shp1 can thus be considered as a regulator of melanoma cell invasiveness and a potential target for antimetastatic drugs. Video abstract.
Sections du résumé
BACKGROUND
Invadopodia are actin-based cell-membrane protrusions associated with the extracellular matrix degradation accompanying cancer invasion. The elucidation of the molecular mechanisms leading to invadopodia formation and activity is central for the prevention of tumor spreading and growth. Protein tyrosine kinases such as Src are known to regulate invadopodia assembly, little is however known on the role of protein tyrosine phosphatases in this process. Among these enzymes, we have selected the tyrosine phosphatase Shp1 to investigate its potential role in invadopodia assembly, due to its involvement in cancer development.
METHODS
Co-immunoprecipitation and immunofluorescence studies were employed to identify novel substrate/s of Shp1AQ controlling invadopodia activity. The phosphorylation level of cortactin, the Shp1 substrate identified in this study, was assessed by immunoprecipitation, in vitro phosphatase and western blot assays. Short interference RNA and a catalytically-dead mutant of Shp1 expressed in A375MM melanoma cells were used to evaluate the role of the specific Shp1-mediated dephosphorylation of cortactin. The anti-invasive proprieties of glycerophosphoinositol, that directly binds and regulates Shp1, were investigated by extracellular matrix degradation assays and in vivo mouse model of metastasis.
RESULTS
The data show that Shp1 was recruited to invadopodia and promoted the dephosphorylation of cortactin at tyrosine 421, leading to an attenuated capacity of melanoma cancer cells to degrade the extracellular matrix. Controls included the use of short interference RNA and catalytically-dead mutant that prevented the dephosphorylation of cortactin and hence the decrease the extracellular matrix degradation by melanoma cells. In addition, the phosphoinositide metabolite glycerophosphoinositol facilitated the localization of Shp1 at invadopodia hence promoting cortactin dephosphorylation. This impaired invadopodia function and tumor dissemination both in vitro and in an in vivo model of melanomas.
CONCLUSION
The main finding here reported is that cortactin is a specific substrate of the tyrosine phosphatase Shp1 and that its phosphorylation/dephosphorylation affects invadopodia formation and, as a consequence, the ability of melanoma cells to invade the extracellular matrix. Shp1 can thus be considered as a regulator of melanoma cell invasiveness and a potential target for antimetastatic drugs. Video abstract.
Identifiants
pubmed: 34088320
doi: 10.1186/s12964-021-00747-6
pii: 10.1186/s12964-021-00747-6
pmc: PMC8176763
doi:
Substances chimiques
Cortactin
0
Inositol Phosphates
0
glycerylphosphoinositol
16824-65-0
Protein Tyrosine Phosphatase, Non-Receptor Type 6
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG18776
Références
Hepatology. 2014 Jan;59(1):190-201
pubmed: 23908138
FASEB J. 2006 Dec;20(14):2567-9
pubmed: 17060404
Nat Rev Cancer. 2009 Apr;9(4):274-84
pubmed: 19308067
Eur J Cancer. 2005 Feb;41(3):470-6
pubmed: 15691648
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11933-8
pubmed: 17606906
J Biol Chem. 2004 Jul 23;279(30):31937-42
pubmed: 15145930
Cell Mol Life Sci. 2009 Nov;66(21):3449-67
pubmed: 19669618
Immunol Rev. 2009 Mar;228(1):342-59
pubmed: 19290938
Biochem Biophys Res Commun. 2004 Nov 26;324(4):1155-64
pubmed: 15504335
Int Rev Cell Mol Biol. 2009;275:1-34
pubmed: 19491051
Theranostics. 2017 Aug 22;7(14):3595-3607
pubmed: 28912898
Eur J Cell Biol. 2014 Oct;93(10-12):438-44
pubmed: 25113547
J Leukoc Biol. 2017 Sep;102(3):657-675
pubmed: 28606940
Oncogene. 2017 Oct 12;36(41):5768-5769
pubmed: 28714962
Eur J Cell Biol. 2011 Feb-Mar;90(2-3):115-27
pubmed: 20609496
Int J Mol Sci. 2017 Jun 08;18(6):
pubmed: 28594363
J Cell Sci. 2010 Nov 1;123(Pt 21):3662-73
pubmed: 20971703
J Biol Chem. 2003 Feb 21;278(8):6516-20
pubmed: 12482860
Cell Commun Signal. 2019 Mar 1;17(1):20
pubmed: 30823936
Methods. 2005 Jan;35(1):44-53
pubmed: 15588985
J Cell Sci. 2008 Feb 1;121(Pt 3):369-78
pubmed: 18198194
J Biol Chem. 1998 Sep 18;273(38):24839-46
pubmed: 9733788
Eur J Cell Biol. 2006 Dec;85(12):1217-31
pubmed: 17010475
Nat Med. 2007 Aug;13(8):992-7
pubmed: 17676052
Commun Integr Biol. 2011 Mar;4(2):205-7
pubmed: 21655441
Mol Biol Cell. 2003 Feb;14(2):503-15
pubmed: 12589050
J Cell Sci. 2012 Apr 1;125(Pt 7):1621-6
pubmed: 22566665
Anticancer Agents Med Chem. 2011 Jan;11(1):89-98
pubmed: 21291405
J Biol Chem. 1996 Apr 26;271(17):10385-90
pubmed: 8626611
J Immunol. 2000 Feb 1;164(3):1521-8
pubmed: 10640770
Future Oncol. 2016 May;12(10):1287-98
pubmed: 26987952
Cells. 2019 Apr 11;8(4):
pubmed: 30979083
J Cell Biol. 2008 Jun 16;181(6):985-98
pubmed: 18541705
Nat Biotechnol. 2002 May;20(5):473-7
pubmed: 11981560
J Biol Chem. 1997 Sep 12;272(37):23376-81
pubmed: 9287352
J Biol Chem. 1997 Aug 22;272(34):21113-9
pubmed: 9261115
J Cell Sci. 2013 Jul 15;126(Pt 14):2979-89
pubmed: 23843616
Theranostics. 2018 Oct 6;8(18):5178-5199
pubmed: 30429893
Oncogene. 2017 Nov 2;36(44):6119-6131
pubmed: 28692056
J Cancer Res Clin Oncol. 2009 Dec;135(12):1791-8
pubmed: 19551406
Neoplasia. 2014 Jul;16(7):595-605
pubmed: 25047655
Cancer Res. 2006 Mar 15;66(6):3034-43
pubmed: 16540652
Proc Natl Acad Sci U S A. 2005 May 10;102(19):6948-53
pubmed: 15870198
Sci Rep. 2017 May 31;7(1):2554
pubmed: 28566721
Biochem Soc Trans. 2012 Feb;40(1):101-7
pubmed: 22260673
J Immunol. 2007 Jul 1;179(1):483-90
pubmed: 17579069
Biochim Biophys Acta. 2008 Dec;1783(12):2311-22
pubmed: 18722484
Small GTPases. 2020 Jul;11(4):256-270
pubmed: 29172953
Cancer Res. 2018 Aug 15;78(16):4680-4691
pubmed: 29776962
Oncol Rep. 2014 May;31(5):2438-46
pubmed: 24647617
Cell Adh Migr. 2011 Mar-Apr;5(2):187-98
pubmed: 21258212
Cancer Res. 2011 Mar 1;71(5):1730-41
pubmed: 21257711
J Cell Biol. 2009 Aug 24;186(4):571-87
pubmed: 19704022
J Biol Chem. 2004 Mar 19;279(12):11375-83
pubmed: 14699166
Cancer Lett. 2012 Aug 1;321(1):27-35
pubmed: 22465052
J Cell Biochem. 2005 Apr 1;94(5):944-53
pubmed: 15578567
Front Oncol. 2020 Jun 11;10:935
pubmed: 32596156
Eur J Med Chem. 2012 Sep;55:220-7
pubmed: 22871485
FEBS J. 2008 Mar;275(5):867-82
pubmed: 18298793
Eur J Cell Biol. 2016 Nov;95(11):483-492
pubmed: 27465307
Oncogene. 1999 Nov 18;18(48):6700-6
pubmed: 10597276
Mol Biol Cell. 1997 Mar;8(3):443-53
pubmed: 9188097
J Cell Biol. 2011 Nov 28;195(5):903-20
pubmed: 22105349
Oncogene. 2015 Oct 8;34(41):5252-63
pubmed: 25619838
Trends Cell Biol. 2017 Aug;27(8):595-607
pubmed: 28412099
Curr Biol. 2013 Nov 4;23(21):2079-89
pubmed: 24206842